Better Health for All

PepGen's entire business is devoted to developing innovative medicines for serious rare neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), aiming to transform treatment by modifying the root cause.

Initial clinical data for PGN-EDODM1 showed mean splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg 28 days post-dosing. The company's R&D budget is entirely focused on health improvement, with over a decade of research on its EDO platform and ongoing Phase 1 and 2 clinical trials. For safety, one treatment-related serious adverse event of abdominal pain occurred in a 10 mg/kg cohort during the FREEDOM-DM1 study, which enrolled 24 adults. The company's Code of Business Conduct and Ethics, adopted April 27, 2022, and amended June 18, 2025, encourages reporting of suspected violations through multiple channels, including anonymous options. PepGen actively seeks community input on its trials to improve them and ensure they are patient-focused. The company provides educational materials about drug development and clinical trials, and its therapies are being investigated in people living with DM1 over the age of 16, and PGN-EDO51 targets approximately 13% of DMD patients.

Fair Money & Economic Opportunity

PepGen Inc. is a biotechnology company focused on developing therapeutics, not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, KPIs related to financial products and services, such as underserved client share, pricing fairness, exploitative fee exposure, data accessibility for customer finance data, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion for financial services, and product simplicity for financial products, are not applicable. While the Compensation Committee may review diversity, equity, and inclusion in human resource strategies, this does not constitute inclusion initiatives related to a loan/insurance book. Profit reinvestment is directed towards ongoing research and clinical development efforts, not community finance or profit-sharing with underserved communities.

Kind to Animals

PepGen Inc. uses non-human primates (NHPs) in preclinical studies for its product candidates, including wild-type NHP studies for PGN-EDO51 and anticipated NHP data for PGN-EDO53 in 2022.

The company also uses the HSALR mouse model for PGN-EDODM1. While the company conducts an in vitro screen of candidate oligonucleotide sequences, preclinical studies mentioned throughout documents imply a reliance on in vivo (animal) testing. There is no explicit animal testing policy provided in the articles, nor are there transparent reduction targets for animal testing volume. Research and development expenses were $25.4 million for the three months ended March 31, 2025, but no specific percentage of this budget is stated as being allocated to animal-free technologies.

Respect for Cultures & Communities

The provided article details PepGen's community engagement efforts focused on neuromuscular disorders, specifically Myotonic Dystrophy Type 1 (DM1), including patient advocacy, clinical trials, and educational resources.

However, it does not contain any specific data, quantitative metrics, or concrete actions relevant to the company's respect for cultures and communities as defined by the rubric, such as partnerships with indigenous groups, cultural impact assessments, local employment ratios, or cultural preservation investments.